Athenex
Conventus Building
1001 Main Street, Suite 600
Buffalo
New York
14203
United States
Tel: 716-427-2950
Website: http://www.athenex.com/
158 articles with Athenex
-
Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
8/11/2022
Athenex intends to use the net proceeds from the proposed offering to fund ongoing clinical development for its product candidates and for working capital and other general corporate purposes.
-
Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Aug 10, 2022
8/10/2022
Athenex, Inc. announced that it intends to offer and sell, subject to market conditions, shares of its common stock, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase shares of its common stock, in an underwritten public offering.
-
Athenex Provides Second Quarter 2022 Financial Results and Business Update
7/28/2022
Athenex, Inc. today provided a corporate and financial update for the second quarter ended June 30, 2022.
-
Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology
7/25/2022
Athenex, Inc., (NASDAQ: ATNX), today announced the publication of their manuscript, “Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer”.
-
Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022
7/21/2022
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the second quarter 2022 on Thursday, July 28, 2022, before the market opens.
-
Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.
7/11/2022
Athenex, Inc. announced that Athenex and certain affiliates have entered into an agreement to sell all of its equity interests in its China subsidiaries, which are primarily engaged in Active Pharmaceutical Ingredient manufacturing operations, to TiHe Capital Co., Ltd. for RMB 124.4 million, or approximately $19.0 million.
-
Athenex to Participate in Truist Securities Cell Therapy Symposium
6/23/2022
Athenex announced that Daniel Lang, M.D., President, Athenex Cell Therapy, will participate in The Next Cells & Mechanisms to Watch in Oncology panel at the Truist Securities Cell Therapy Symposium on Tuesday, June 28, 2022 at 11:30 am Eastern Time in New York, NY.
-
Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree
6/22/2022
Athenex, Inc., (NASDAQ: ATNX), today announced the signing of a definitive agreement for the sale of revenues from U.S. and European royalty and milestone interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and funds managed by Oaktree Capital Management, L.P. (“Oaktree”) for $85 million.
-
Third Harmonic Bio, Akili Interactive, the Rare Disease Company Coalition, Inozyme, Athira, Cytovia and many more made major leadership decisions this week.
-
Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy
6/8/2022
Athenex, Inc. announced the appointment of Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to lead its clinical development, clinical operations, and regulatory affairs functions.
-
Athenex Provides First Quarter 2022 Financial Results and Business Update
5/10/2022
Athenex, Inc. provided a corporate and financial update for the first quarter ended March 31, 2022.
-
A roundup of last week's top clinical trial updates and news.
-
Athenex to Provide Corporate and Financial Update for the First Quarter 2022 on May 10, 2022
4/29/2022
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the first quarter 2022 on Tuesday, May 10, 2022, before the market opens.
-
Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular (“Tandem”) Meetings of ASTCT and CIBMTR
4/25/2022
Athenex, Inc., (NASDAQ: ATNX), today announced data from the ANCHOR Phase 1 study of KUR-502 during an oral presentation by Carlos Ramos, M.D., professor, Center for Cell and Gene Therapy, Baylor College of Medicine, at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT), and the Center for International Blood & Marrow Transplant Research (CIBMTR).
-
Athenex announced that it is scaling its operations by more than 50%, while Zosano Pharma announced that it is reducing its workforce by around 31%.
-
Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
3/16/2022
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2021.
-
CORRECTION: Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 16, 2022
3/14/2022
Athenex, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2021, on Wednesday, March 16, 2022.
-
Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 15, 2022
3/7/2022
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2021, on Tuesday, March 15, 2022.
-
Athenex Announces Appointment of Chief Financial Officer
2/22/2022
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately.
-
Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility
2/15/2022
Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced the close of the sale of its leasehold interest in a manufacturing facility in Dunkirk, New York, to ImmunityBio, Inc., for approximately $40 million.